Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy OfficerNovember 16, 2020
Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical OfficerAugust 10, 2020
Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business JournalAugust 3, 2020
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual CongressJuly 12, 2020
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature MedicineJune 1, 2020
